News View All News arrow-button

Jun 03, 2020

IFM Therapeutics Welcomes Two New Leadership Team Members

IFM Therapeutics is pleased to announce the appointment of Maegan E. Deare as Vice President of Legal and Christopher M. Lindblom as Vice President of Finance.

Maegan Deare brings over eight years of experience leading and advising on legal aspects associated with mergers and acquisitions, strategic transactions, business development, financings, corporate governance and regulatory efforts. She previously worked at Foundation Medicine and Finch Therapeutics, Inc.

Christopher Lindblom’s 18-year career spans experience in both public and private biotech companies, driving long-range financial plans in concert with strategic planning. He has played a key role in helping biotech companies raise capital, from confidential follow-on offerings for public companies to private equity rounds and venture debt deals. Prior to joining IFM, he served as Vice President of Finance at Cogen Immune Medicine, and previously served in senior finance roles at Warp Drive Bio, Millennium Pharmaceuticals, Ovascience and BIND Therapeutics.

About IFM Therapeutics, LLC

IFM Therapeutics (IFM) is an independent, privately-held biopharmaceutical company based in Boston, Massachusetts. IFM’s team has discovered and developed small molecules that modulate novel targets in the innate immune system as next-generation therapies for cancer, autoimmunity, and inflammatory disorders. IFM places each program (or set of related programs) in its own dedicated, independently financed, R&D-focused subsidiary company, which is supported by the common infrastructure, management team and resources of the IFM enterprise. For more information on IFM and its model, please visit

Media Contact

Cherise Adkins
Spectrum Science